Honing Biosciences

Honing Biosciences, inventing the next generation cellular therapiesHoning Biosciences is a bio-therapeutics company that develops and improves cell-based therapies in particular of cancer and other chronic diseases. Cell-based approaches represent a promising avenue to develop novel therapies. Honing Biosciences leverages technologies that allow precise control of cell functions after delivery to patients, increasing the efficacy and limiting the harmful drawbacks of previous generations of treatments. Our molecular CellTuneTM technology allows to develop new classes of tunable cell therapeutics to control the dynamic delivery of proteins in patients. We can thus regulate protein expression at the cell surface or secretion of enzymes, cytokines, antibodies, adapting the delivery of therapeutic proteins to clinical evolutions. Honing Biosciences proprietary technological platform has breakthrough applications all types of cell-based therapy, including immunotherapy and reconstituting cell therapies for autoimmunity and chronic diseases.

Scientific team

Franck PEREZFranck is Research Director at CNRS and group leader in the Cell Biology Section of the Curie Institute (Paris, France). His group is studying intracellular trafficking in human cells, asking how cell can control constant ows of protein secretion and ensure its homeostasis.
His work has always been accompanied by an important focus on the development of new methods and tools for Cell Biology studies. For example, he developed at the Institut Curie the use of automated cellular screening and co-founded a High Content screening platform (BioPhenics, with D. J. Camonis). In addition, his group has strongly invested on the development of recombinant antibodies for cell biology using antibody phage display.
Recently, he created a novel antibody library based on a humanized single domain scaffold and, in association with Dr. S. Amigorena, created a therapeutic antibody platform.
Dr. F. Perez is member of the Board of the Institut Curie, Scientfic Director of the cell screening platform Biophenics and of the Therapeutic Antibody platform TAbIP and the head of the "Dynamics of Intracellular Organization" team at the Institut Curie. He should become the Director of Cell Biology Unit (CNRS UMR144) of the Institut Curie in 2017. He authored more than 80 scientific articles and filled and licensed several patents.
Sebastian AMIGORENASebastian is director of the INSERM lab 932 (Immunity and Cancer) and head of the Immunology and Immunotherapy department at Institut Curie.
The research of Sebastian AMIGORENA lies at the border between cell biology, immunology and cancer. He made critical contributions to our understanding of the molecular and cell biological mechanisms of antigen presentation to T lymphocytes.
His team defined the endocytic routes and the intracellular compartments involved in MHC class I- and class II-restricted antigen presentation. They also described the molecular mechanisms of phagosome pH regulation in dendritic cells, and analyse the mechanisms of recruitment of endoplasmic reticulum-resident proteins to phagosomes. They described functionally and characterized biochemically the exosomes produced by dendritic cells and contributed to the first phase clinical trials using exosomes as vaccination vectors.
Sebastian Amigorena's team also used two-photon intravital microscopy to analyse the interactions between dendritic cells and T lymphocytes, and to characterize the role of regulatory T cells in the regulation of this process.
More recently, the Amigorena team analysed phenotypically and functionally human dendritic cells in human secondary lymphoid organs from cancer patients, including lymph nodes, tonsils and inflammatory environments.


Institut CurieInstitut Curie, a leading player in the fight against cancer, combines a leading French research center in oncology and a state-of-the-art hospital group that treat all types of cancer, including the rarest. Founded in 1909 by Marie Curie, the Institut Curie brings together more than 3,300 researchers, physicians and healthcare professionals around its three missions: care, research and teaching. As a private foundation recognized for public utility, Institut Curie is authorized to receive donations and bequests and can, thanks to the support of its donors, accelerate discoveries and thus improve the treatment and the quality of life of the patients.
Since 2011, Institut Curie is certified "Institut Carnot Curie Cancer". The Carnot label is a label of excellence granted to academic research structures with proven high quality and involvement in partnership research. Curie Cancer offers industrial partners the opportunity to set up research collaborations, benefiting from the expertise of the Institut Curie teams, for the development of innovative therapeutic solutions against cancers from the therapeutic target to clinical validation.
Abdelkader BOUSABAAAbdelkader is professor of Finance in Paris. He was head of quantitative research at Rothschild and has 18 years of international investment banking experience in risk management and quantitative research. He covers many aspects of risk monitoring, taking a cross-asset class approach to market risks.
Abdelkader professional experience includes positions in both risk management and capital markets. Previous position includes Financial Engineer at Credit Agricole / Credit Lyonnais in the GRO, Operational Research Group : operational research on pricing models, asset management, risk monitoring and regulatory.
Abdelkader founded and managed numerous companies in France, UK, USA and Hong Kong. Nevertheless, he preserves a continuous flow between academic environment and capital market activities. He has been teaching various courses including Numerical Methods in Finance, Asset-Liability Management, Risk Management, Financial Regulation, Credit Derivatives... in various universities (Dauphine, Paris-Saclay, ENSAI, Rennes...).